Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
We share a TV news report about a Maryland mother who advocated for her son and then learned she also had a primary immune de…
We share a news report from California about a mother-daughter duo who share a diagnosis with primary immune deficiency.
We share a recent sponsored article in Politico and reports from Danish news outlets.
Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease…
We share a report about a 24-year-old with hemophilia B who recently received gene therapy in California.
An associate professor living with Hereditary Angioedema encourages fellow patients to “never give up and try to persist in y…
We share a report about a 32-year-old with hemophilia B who recently received gene therapy at Harvard-affiliated Brigham and …
We share reports about a 57-year-old and 63-year-old with hemophilia B who recently received gene therapy.
Tim Grams, father of four, dove into swimming as a young person and today stays active despite Hemophilia A.
A high school senior, Jack recalls more than a decade of swelling attacks due to hereditary angioedema, including a life-thre…
Lexi lives with the rare disease hereditary angioedema (HAE). She reflects on how the condition’s random swelling attacks imp…
Danielle, who has a primary immunodeficiency, took on pregnancy and motherhood with determination. Now, she and her husband a…
Americas
Asia Pacific
Middle East
Europe
